Parametric Tolerance Interval Testing Working Group To Deliver Findings By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA believes the method is an improvement over non-parametic testing but is seeking to resolve outstanding safety issues, the agency tells the Pharmaceutical Science Advisory Committee.
You may also be interested in...
FDA's "Critical Path" Leads To Pharmaceutical Science Advisory Committee Meeting
The committee will discuss research opportunities under FDA's "Critical Path" initiative. Other topics for the Oct. 19-20 meeting include manufacturing, the risk-based GMP initiative, parametrics and generic drug equivalence.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.